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Abstract
Background: One intractable problem with using microarray data analysis for cancer classification
is how to reduce the extremely high-dimensionality gene feature data to remove the effects of
noise. Feature selection is often used to address this problem by selecting informative genes from
among thousands or tens of thousands of genes. However, most of the existing methods of
microarray-based cancer classification utilize too many genes to achieve accurate classification,
which often hampers the interpretability of the models. For a better understanding of the
classification results, it is desirable to develop simpler rule-based models with as few marker genes
as possible.
Methods: We screened a small number of informative single genes and gene pairs on the basis of
their depended degrees proposed in rough sets. Applying the decision rules induced by the selected
genes or gene pairs, we constructed cancer classifiers. We tested the efficacy of the classifiers by
leave-one-out cross-validation (LOOCV) of training sets and classification of independent test sets.
Results: We applied our methods to five cancerous gene expression datasets: leukemia (acute
lymphoblastic leukemia [ALL] vs. acute myeloid leukemia [AML]), lung cancer, prostate cancer,
breast cancer, and leukemia (ALL vs. mixed-lineage leukemia [MLL] vs. AML). Accurate
classification outcomes were obtained by utilizing just one or two genes. Some genes that
correlated closely with the pathogenesis of relevant cancers were identified. In terms of both
classification performance and algorithm simplicity, our approach outperformed or at least
matched existing methods.
Conclusion: In cancerous gene expression datasets, a small number of genes, even one or two if
selected correctly, is capable of achieving an ideal cancer classification effect. This finding also means
that very simple rules may perform well for cancerous class prediction.
Background
Rapid advances in gene expression microarray technology
have enabled the simultaneous measurement of the
expression levels of tens of thousands of genes in a single
experiment [1]. By measuring gene expression levels
related to multiple individuals and multiple tissue or
tumor samples, investigators can discover molecular
markers to be used for cancer diagnosis, prognosis, and
prediction. Many researchers have explored the use of
microarray technology to build cancer diagnosis, progno-
sis, and prediction classifiers, since the pioneering work of
Golub et al. in applying gene expression monitoring by
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DNA microarray to cancer classification [2]. However, one
intractable problem with using microarray data analysis
to create cancer classifiers is how to reduce the exceedingly
high-dimensional gene expression data, which contain a
large amount of noise. On the other hand, compared with
the measured quantities of gene expression levels in
experiments, the numbers of samples are severely limited.
This brings about two computational challenges: compu-
tational cost and classification accuracy. To achieve effi-
cient and accurate classification, it is natural for
researchers to investigate feature selection; i.e., gene filter-
ing [3]. However, one serious drawback of most existing
methods is that too many genes are ultimately selected for
the classification of cancer, thereby hampering the inter-
pretability of the models. In fact, it is not easy to gauge
which gene is essential in determining a cancerous class if
accurate classification is obtained based on a large cluster
of genes.
In parallel with feature selection, classifier construction is
an important topic in this field. In machine learning and
data mining, the methods of generating classifiers include
unsupervised and supervised approaches. The latter is fur-
ther classified into two categories: "black-box" and
"white-box" models. The "black-box" models, such as
support vector machines (SVMs), discriminant analysis
(DA), artificial neural networks (ANNs), genetic algo-
rithms (GAs), naïve Bayes (NB), and k-nearest neighbors
(k-NNs), address classification problems without any
knowledge-based explanation rules. In contrast, the
"white-box" models, such as Decision Trees [4], Rough
Sets [5], and emerging patterns (EPs) [6], often imple-
ment classification by giving "IF-THEN"-like rules. The
"white-box" models are sometimes more welcomed by
biologists and clinicians because they are easily under-
stood.
Many investigators have utilized the rule-based
approaches (i.e., "white-box" models) to produce cancer
classifiers [6-13]. In general, these classifiers involve few
genes, whereas they exhibit efficient prediction perform-
ance. In [6], the authors proposed one method of identi-
fying good diagnostic gene groups from gene expression
profiles using the concept of EPs. The authors sought to
find the gene groups whose frequency of patterns changed
significantly between two classes of cells. They then used
the rules arising from these patterns to construct cancer
classifiers. Their classifiers were uncomplicated, as they
merely contained the rules involving a few genes. In [11],
decision tree algorithms involving single C4.5, Bagging,
and AdaBoost decision trees were applied to classify gene
expression datasets. In essence, a decision tree is a rule-
based classifier. The classifier screens the informative fea-
tures to build decision trees based on the information
entropy concept. Subsequently, rules are derived from the
trees. Because decision tree algorithms commonly con-
duct pruning of the trees to remove unnecessary features,
the derived rules generally involve only a small number of
features. In [13], the authors proposed the use of high-
ranked association rule groups to construct cancer classifi-
ers instead of utilizing all of the mined association rules,
which commonly involves excessive numbers of redun-
dant rules.
Some investigators have addressed the problem of using
pairs of genes to conduct cancer classification. In [14], the
authors classified gene expression profiles using a com-
parison-based approach, the "top-scoring pair(s)," called
the TSP classifier. The authors attempted to predict classes
by comparing the expression levels of a single pair of
genes, chosen based on a simple measure of class discrim-
ination. In [15], the authors investigated the use of gene
pairs for classification. They screened the gene pairs that
had marked differences in average expression levels
between the tumor types in the training set. The gene pairs
were then applied to classify test sets.
Rough sets, a data-analysis method originally proposed by
Pawlak in the early 1980s [5], has evolved into a widely
accepted machine-learning and data-mining method [16].
In [7-10], rough sets was applied for cancer classification
and prediction based on an attribute reduction approach.
In [17], we proposed a rough sets-based soft computing
method to conduct cancer classification using single genes
or gene pairs. In this article, we also explore the use of sin-
gle genes and gene pairs in constructing cancer classifiers;
however, in contrast to [17], we first aimed to use the con-
cept of canonical depended degree, as proposed in rough
sets for gene selection. In the cases that this approach was
unsuccessful, we considered utilizing the α  depended
degree standard suggested in [17] for gene selection. In
this work, the α depended degree was employed for a por-
tion of the datasets. In addition, unlike the other rough
sets-based methods, we did not carry out attribute reduc-
tion for gene selection. Instead, we first implemented fea-
ture ranking according to the depended degree or α
depended degree of attributes, and then selected the top-
ranked genes to create classifiers so as to avoid expensive
computation for attribute reduction. Moreover, we made
use of the decision rules induced by the chosen genes to
build classifiers, whereas existing rough sets-based meth-
ods only utilized rough sets for gene selection, and the
classifier constructions depended upon other machine-
learning algorithms such as SVMs, ANNs, GAs, NB, and k-
NNs [7-10].
We tested the methods in the five publicly available gene
expression datasets: Leukemia 1 (ALL vs. AML), Lung Can-
cer, Prostate Cancer, Breast Cancer, and Leukemia 2 (ALL
vs. MLL vs. AML), which can be downloaded from theBMC Medical Genomics 2009, 2:64 http://www.biomedcentral.com/1755-8794/2/64
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Kent Ridge Bio-medical Data Set Repository http://
datam.i2r.a-star.edu.sg/datasets/krbd/. We compared our
results with the findings of previous studies. Furthermore,
we examined and analyzed the biological relevance of the
selected genes.
Methods
Rough sets
In rough sets, an equivalence relation on U is referred to
as one knowledge, and a family of equivalence relations is
referred to as a knowledge base on U. In reality, we are often
faced with a large amount of ill-defined data, and we want
to learn about them based on pre-existing knowledge.
However, most of these data cannot be precisely defined
based on pre-existing knowledge, as they incorporate both
definite and vague components. In [5], Pawlak describes
the definite parts using the concept of positive region.
Definition 1 Let U be a universe of discourse, X ⊆ U, and
R is an equivalence relation on U. U/R represents the set
of the equivalence class of U induced by R. The positive
region of X on R in U is defined as pos(R, X) = ∪ {Y ∈ U/R
| Y ⊆ X}[5].
The decision table is the data form studied by rough sets.
One decision table can be represented as S = (U, A = C ∪
D), where U  is the set of samples, C  is the condition
attribute set, and D is the decision attribute set. Without
loss of generality, hereafter we assume D is a single-ele-
ment set, and we call D the decision attribute. A can be
viewed as a knowledge base in S, as each attribute or
attribute subset can induce an equivalence relation on U.
In the decision table, if we designate Ia as the function
mapping a member (sample) of U to the value of the
member on the attribute a (a ∈ A), then the equivalence
relation R(A') induced by the attribute subset A' ⊆ A is
defined as: for ∀x, y ∈ U, xR(A')y, if and only if Ia(x) = Ia(y)
for each a ∈ A'.
For the cancer classification problem, every collected set
of microarray data can be represented as a decision table
in the form of Table 1. In the microarray data decision
table, there are m samples and n genes. Every sample is
assigned to one class label. The expression level of gene y
in sample x is represented by g(x, y).
In rough sets, the degree of dependency of a set of attributes
Q on another set of attributes P is denoted by γP(Q) and is
defined as
Where   represents the
size of the union of the lower approximation of each
equivalence class in U/R(Q) on P in U, and |U| represents
the size of U (set of samples).
If Q is the decision attribute D, and P is a subset of condi-
tion attributes, then γP(D) represents the depended degree
of the condition attribute subset P  by the decision
attribute D; that is, to what degree P can discriminate the
distinct classes of D. In this sense, γP(D) reflects the classi-
fication power of the subset P of attributes. The greater is
γP(D), the stronger the classification ability P is inclined to
possess. We chose the measure of the depended degree of
condition attributes by class attributes as the basis for
selecting informative genes.
In contrast to other correlation-based feature selection
standards such as t-score, the depended degree can be calcu-
lated only when the attribute values are discrete. Thus, for
the studied microarray datasets, the discretization of gene
expression values is an essential step. Indeed, the discreti-
zation will bring about several advantages. First, some
unimportant genes will be found immediately after the
discretization. When the discretized expression values of a
gene are identical among all of the samples, we view the
gene as being insignificant because distinct classes cannot
be separated according to the gene's expression values.
Second, when gene expression values are reduced to dis-
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Table 1: Microarray data decision table
Samples Condition attributes (genes) Decision attributes (classes)
Gene 1 Gene 2 ... Gene n Class label
1 g(1,1) g(1,2) ... g(1, n) Class (1)
2 g(2,1) g(2,2) ... g(2, n) Class (2)
... ... ... ... ... ...
mg (m,1) g(m,2) ... g(m, n) Class (m)BMC Medical Genomics 2009, 2:64 http://www.biomedcentral.com/1755-8794/2/64
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crete states, the rules formed by the genes can be described
naturally via the discretized data.
However, for some datasets it is difficult to detect the dis-
criminative features based on the depended degree
because of its excessively rigid definition. In this case, we
employed the α depended degree proposed in [17] as the
basis for choosing genes. The α depended degree of an
attribute subset P by the decision attribute D is defined as
, where 0 ≤  α  ≤ 1,
 and pos(P, X, α) =
∪{Y ∈ U/R(P) | |Y ∩ X|/|Y|≥ α} [17]. In fact, as indicated
in [17], the depended degree is a specific case of the α
depended degree when α  = 1. In the case that the
depended degree was largely ineffective as a basis on
which to screen features, we employed the α (0.7 ≤ α < 1)
depended degree.
Inducing decision rules that are hiding in decision tables
is one of the key tasks of rough sets, which is also an essen-
tial procedure of our classifier construction. One decision
rule in the form of "A ⇒ B" indicates that "if A, then B,"
where A is the description of condition attributes and B
the description of decision attributes. The confidence of a
decision rule A  ∧  B  is defined as follows:
, where support(A)
denotes the proportion of the samples satisfying A and
where support(A ∧ B) denotes the proportion of the sam-
ples satisfying A and B simultaneously. The confidence of
a decision rule indicates the reliability of the rule. If a deci-
sion rule had 100% confidence, we called it a consistent
decision rule. It is evident that if γP(D) equals 1, P ⇒ D
must be a consistent decision rule. In contrast, γP(D, α) =
1 does not mean that P ⇒ D must be a consistent decision
rule.
To ensure the reliability of the classification rules, we
chose only the genes or gene pairs with γP(D) or γP(D, α)
equal to 1 when forming decision rules. Suppose g is one
of the selected genes and U is the sample set. U/R(g) =
{c1(g), c2(g), ..., cn(g)} represents the set of the equiva-
lence class of samples induced by R(g). Two samples, s1
and s2, belong to the same equivalence class of U/R(g) if
and only if they have the same value on g. In addition, we
represented the set of the equivalence class of samples
induced by R(D) as U/R(D) = {d1(D), d2(D), ..., dm(D)},
where D is the decision attribute. Likewise, two samples,
s1 and s2, belong to the same equivalence class of U/R(D)
if and only if they have the same value on D. For each ci(g)
(i = 1, 2, ..., n), if there exists some dj(D) (j ∈ {1, 2, ...,
m}), satisfying ci(g)  ⊆ d j(D) in light of the depended
degree or |ci(g)  ∩ d j(D)|/|ci(g)|≥  α  in light of the α
depended degree, we then generated the following classi-
fication rule: A(ci(g)) ⇒ B(dj(D)), where A(ci(g)) is the
formula describing the sample set ci(g) by the g value, and
B(dj(D)) is the formula describing the sample set dj(D) by
the class value. We used the same strategy to construct
classification rules for gene pairs.
In the case of the depended degree, each employed classi-
fication rule was the consistent decision rule. However, in
the case of the α depended degree, the classification rules
may not have been consistent, yet the confidence of every
classification rule must be no less than α, as proven in
[17]. Hence, if we specified a large enough α threshold,
the confidence of classification rules would have been suf-
ficiently high.
Datasets
Leukemia dataset 1 (ALL vs. AML)
The first dataset we analyzed was the well-known leuke-
mia data studied by Golub et al. [2], which has been
explored widely by many researchers. In this dataset, there
are 72 observations, each of which is described by the
gene expression levels of 7129 genes and a class attribute
with two distinct labels: AML vs. ALL. The 72 observations
are divided into a training set with 38 samples (27 ALL, 11
AML) and a test set with 34 samples (20 ALL, 14 AML).
Lung Cancer dataset
The Lung Cancer dataset is a classification of malignant
pleural mesothelioma (MPM) vs. adenocarcinoma
(ADCA) of the lung [15], and consists of 181 tissue sam-
ples (31 MPM, 150 ADCA). The training set contains 32
of the samples (16 MPM vs. 16 ADCA); the remaining 149
samples are used for testing. Each sample is described by
12,533 genes.
Prostate Cancer dataset
The Prostate Cancer dataset is concerned with prostate
tumor vs. normal classification. The training set contains
52 prostate tumor samples and 50 non-tumor prostate
samples [18]; the total number of genes is 12,600. Two
classes are denoted as "Tumor" and "Normal." The test set
samples were from a different experiment and have a
nearly 10-fold difference in overall microarray intensity
compared with the training data. We made use of the test
set provided by Kent Ridge Bio-medical Data Set Reposi-
tory, which includes 25 tumor and 9 normal samples.
ga
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Breast Cancer dataset
This dataset is concerned with the prediction of patient
outcome for breast cancer [19]. The training set contains
78 patient samples, 34 of which are from patients who
had developed distant metastases within 5 years
("relapse"); the remaining 44 samples are from patients
who remained healthy from the disease for an interval of
at least 5 years after initial diagnosis ("non-relapse").
There are 12 relapse and 7 non-relapse samples in the test
set, and the number of genes is 24,481.
Leukemia dataset 2 (ALL vs. MLL vs. AML)
This dataset is about subtype prediction for leukemia [20].
The training set contains 57 samples (20 ALL, 17 MLL,
and 20 AML), while the testing set contains 15 samples (4
ALL, 3 MLL, and 8 AML). The number of genes is 12,582.
The gene number, class, training sample number and test
sample number contained in the five datasets are listed in
Table 2.
Data preprocessing
Normalization of attributes value
Because the training set samples and the test set samples
in the prostate cancer dataset are from two different exper-
iments, and because discrepancies in microarray intensity
exist between the two sets of samples, we normalized both
the training set and the test set. Suppose that the original
expression level of gene y in sample x is g(x, y). Then, the
normalized value of g(x,  y) is
, where max g(￿, y) and min
g(￿, y) represent the maximum and the minimum expres-
sion levels of gene y in all of the samples, respectively.
After normalization, all of the expression levels of the
genes lie within the interval [-1, 1]. As a result, we can
apply the rules induced in the training set to the test set.
Because the training set samples and the test set samples
in the other datasets are from the same experiments, we
chose not to normalize these data to avoid any loss of
information.
Discretization of decision tables
Because rough sets is suitable for handling discrete
attributes, we needed to first discretize the training set
decision tables. We used the entropy-based discretization
method, as first proposed by Fayyad et al. [21]. This algo-
rithm recursively applies an entropy minimization heuris-
tic to discretize the continuous-valued attributes. The stop
of the recursive step for this algorithm depends on the
minimum description length (MDL) principle. We imple-
mented the discretization in the Weka package [22]. After
the discretization, the majority of attributes contained at
most two distinct values, while a small number of
attributes contained three or four distinct values. We exe-
cuted our learning algorithm in the discretized decision
tables.
Feature selection, classifier construction, and validation
For the Leukemia 1 and Lung Cancer datasets, we con-
ducted feature selection by the depended degree, while for
the Prostate Cancer, Breast Cancer and Leukemia 2 data-
sets, we implemented feature selection by the α depended
degree. For each dataset, we employed the LOOCV
approach for the training set to identify high class-dis-
crimination genes or gene pairs. That is, in the training set
containing n samples, each sample is left out in turn, and
the learning algorithm is trained on the remaining n-1
samples. Then, the training result is tested on the left-out
sample. The final estimate is the average of n test results.
We emphasize that only the single genes or gene pairs
chosen by all of the leave-one-out training sets are used
for LOOCV. In other words, when the depended degree
standard is utilized, only those genes or gene pairs with a
100% depended degree in all leave-one-out training sets
are selected; when the α  depended degree standard is
used, only the genes and gene pairs satisfying γP(D, α) = 1
in all of the leave-one-out training sets are chosen. Accord-
ing to the results of LOOCV, we finally determined the
informative genes or gene pairs. Applying the classifica-
tion rules induced by the single genes or gene pairs in the
entire training set to classify the independent test set, we
further verified their classification performance.
gxy g y g y
gy gy
( , ) (max ( , ) min ( , ))/
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Table 2: Summary of the five gene expression datasets
Dataset # Original genes Class # Training samples # Test samples
Leukemia 1 7129 ALL/AML 38 (27/11) 34 (20/14)
Lung Cancer 12533 MPM/ADCA 32 (16/16) 149 (15/134)
Prostate Cancer 12600 Tumor/Normal 102 (52/50) 34 (25/9)
Breast Cancer 24481 relapse/non-relapse 78 (34/44) 19 (12/7)
Leukemia 2 12582 ALL/MLL/AML 57 (20/17/20) 15 (4/3/8)BMC Medical Genomics 2009, 2:64 http://www.biomedcentral.com/1755-8794/2/64
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Results
Classification results
Leukemia dataset 1
In this dataset, we first selected informative single genes.
Among the 7129 genes, only gene #4847 had a 100%
depended degree in all leave-one-out training sets. We
denoted the expression level of gene x by g(x). The deci-
sion rules induced by gene #4847 in every leave-one-out
training set are of the following form: if g(#4847) > t, then
AML; if g(#4847) ≤ t, then ALL, where t is equal or close
to 994. One can apply the decision rules to classify the
left-out sample. The final LOOCV accuracy resulting from
the gene was 97.4%, with 37 of the 38 samples classified
correctly, wherein all of the 27 ALL samples were classified
correctly, and one AML sample was misclassified. Subse-
quently, we examined the depended degree of the gene in
the whole training set of 38 samples. As expected, the gene
had a 100% depended degree in the training set. The two
consistent decision rules generated by this gene were as
follows: if g(#4847) > 994, then AML; if g(#4847) ≤ 994,
then ALL. One can use the above rules to classify the inde-
pendent test set with 91.2% classification accuracy.
Among the 34 samples, 31 were classified correctly and 3
were classified incorrectly: 2 ALL samples were misclassi-
fied into AML, and 1 ALL sample was misclassified into
AML.
Next, we searched for informative gene pairs. Because
there are 7129 genes, the combination number would be
huge if all were taken into account. Therefore, for each
leave-one-out training set, only the genes with more than
18/37 depended degree were considered in forming gene
pairs (excluding the aforementioned gene #4847). As a
result, 350 gene pairs were found to possess a 100%
depended degree in all leave-one-out training sets. Every
gene pair was capable of inducing four consistent decision
rules, which were used for classification. We set the
threshold of LOOCV accuracy such that at least 35 of the
38 samples were classified correctly. Accordingly, 347
gene pairs satisfied the condition. Likewise, using the
decision rules induced by the gene pairs in the whole
training set to classify the test set, we detected 13 gene
pairs with no less than 32 test samples classified correctly
(at most, 2 errors). Table 3 lists data for these 13 pairs of
genes. In this table, the classification results regarding
LOOCV and the test set are shown in terms of both the
number of correctly classified samples and accuracy. The
Table 3: Thirteen gene pairs with high classification accuracy in the Leukemia dataset 1
1st - 2nd Probe ID Classification results in LOOCV Classification results in the test set
# Correctly classified samples Accuracy (%) # Correctly classified samples Accuracy (%)
U46499_at - M92287_at 35 (26/9) 92.11 (96.30/81.82) 33 (20/13) 97.06 (100/92.86)
U46499_at - M12959_s_at 36 (27/9) 94.74 (100/81.82) 34 (20/14) 100 (100/100)
U46499_at - D63880_at 36 (27/9) 94.74 (100/81.82) 33 (20/13) 97.06 (100/92.86)
U46499_at - S50223_at 37 (27/10) 97.37 (100/90.91) 33 (19/14) 97.06 (95/100)
U46499_at - Z15115_at 35 (26/9) 92.11(96.30/81.82) 33 (20/13) 97.06 (100/92.86)
L09209_s_at - M92287_at 37 (27/10) 97.37 (100/90.91) 33 (20/13) 97.06 (100/92.86)
L09209_s_at - S50223_at 37 (27/10) 97.37 (100/90.91) 33 (19/14) 97.06 (95/100)
X61587_at - M92287_at 36 (26/10) 94.74 (96.30/90.91) 33 (20/13) 97.06 (100/92.86)
X61587_at - M12959_s_at 37 (27/10) 97.37 (100/90.91) 33 (19/14) 97.06 (95/100)
L09209_s_at - D63880_at 37 (27/10) 97.37 (100/90.91) 32 (19/13) 94.12 (95/92.86)
U05259_rna1_at - M92287_at 36 (26/10) 94.74 (96.30/90.91) 32 (20/12) 94.12 (100/100)
L09209_s_at - X59417_at 37 (27/10) 97.37 (100/90.91) 32 (19/13) 94.12 (95/92.86)
L09209_s_at - Z15115_at 37 (27/10) 97.37 (100/90.91) 32 (19/13) 94.12 (95/92.86)BMC Medical Genomics 2009, 2:64 http://www.biomedcentral.com/1755-8794/2/64
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results with respect to every class are presented in paren-
theses, and the optimal results are formatted in boldface.
Among the 13 gene pairs, the combination #3252-#6167
possessed 100% classification accuracy on the test set. The
decision rules produced by the gene pair were as follows:
￿ if g(#3252) ≤ 156.5 and g(#6167) > 820.5, then ALL;
￿ if g(#3252) ≤ 156.5 and g(#6167) ≤ 820.5, then ALL;
￿ if g(#3252) > 156.5 and g(#6167) > 820.5, then ALL;
￿ if g(#3252) > 156.5 and g(#6167) ≤ 820.5, then
AML.
The above rules were then simplified into three equivalent
rules:
￿ if g(#3252) ≤ 156.5, then ALL;
￿ if g(#6167) > 820.5, then ALL;
￿ if g(#3252) > 156.5 and g(#6167) ≤ 820.5, then
AML.
These three rules are fairly simple and easily understood.
Using these rules, we classified the test set without any
errors. The rules derived from the other 12 gene pairs are
provided in the Additional file 1, and we also provide
information on the top 87 genes in the training set with
depended degrees of no less than 0.5 in the Additional file
2.
Lung Cancer dataset
This dataset contained 16 genes with a 100% depended
degree in all of the 32 leave-one-out training sets. The
LOOCV accuracy of the 16 genes was between 93.75%
and 100%. Namely, the number of correctly classified
samples ranged from 30 to 32. In the training set, each of
the 16 genes had a 100% depended degree. These obser-
vations indicate that each single gene among the 16 genes
was likely to have high class-discriminative power in the
training set. Using the rules generated by these single
genes, we examined the test set. As expected, these genes
showed high classification performance, with classifica-
tion accuracy ranging from 79% to 97%. The classification
results are presented in Table 4, which shows that some of
the genes in the Lung Cancer dataset, such as gene
37716_at, have impressive classification performance.
The rules induced by gene 37716_at were the following: if
g(37716_at) > 197.75, then mesothelioma; if
g(37716_at) ≤ 197.75, then ADCA. Using these two rules,
we could classify the test set with 97% accuracy. The rules
produced by the 16 genes are provided in the Additional
file 3. From these rules, we suspected that 2047_s_at,
2266_s_at, 32046_at, 33245_at, 41286_at, 41402_at,
575_s_at, and 988_at have higher expression levels in
ADCA, while the others have higher expression levels in
mesothelioma.
If more than one gene is considered when developing
rules, higher classification accuracy should be achieved.
Therefore, we carried out further classification tests using
gene pairs. As before, we tried to find the gene pairs with
high LOOCV accuracy. To avoid combination explosion,
to constitute gene pairs we only selected genes with more
than 12/31 and less than 100% depended degree in all 32
leave-one-out training sets. Furthermore, to avoid intri-
cate classification rules produced by gene pairs, we
excluded genes with more than two distinct discretized
values. Accordingly, we found 82 gene pairs with a 100%
depended degree in all 32 leave-one-out training sets.
Among them, 25 pairs possessed 100% LOOCV accuracy.
These pairs also had comparatively strong classification
power in the test set. Their classification accuracy was
between 71.14% and 96.64%; 21 pairs showed accuracy
exceeding 80%, and nine pairs had accuracy exceeding
90%. Data for these 25 gene pairs are listed in Table 5. The
classification rules induced by these pairs are presented in
the Additional file 3.
To observe the relationship between the depended
degrees of single genes and the classification accuracy of
gene pairs, we carried out another experiment. In the dis-
cretized training set, we first excluded the genes with
depended degrees 0 and 100%, as well as the genes with
above two distinct values. As a result, there were 1428
genes left for pair combination. We set the threshold
number of correctly classified samples as 148; that is, we
searched for the gene pairs by which the test set are classi-
fied with at most one error. In addition, we set another
threshold k, and required that the sizes of the positive
regions caused by the selected genes must exceed k, with k
varying from 13 to 0. When k equals 13, 61 genes are
selected, and 743 pair combinations have 100%
depended degree. Using the rules derived from each of the
743 gene pairs to classify the test set, we detected 4 com-
binations with 148 samples classified correctly. When k
was 12, 11, and 10, only the same four combinations were
found. When k decreased to 9 and 8, five and seven com-
binations were found, respectively. At lower values, no
more combinations were found to classify 148 samples or
more correctly, even when k was reduced to 0, and the
selected gene number is 1428 accompanied by 33,390
combinations with a 100% depended degree. The results
indicate that combinations between genes with higher
depended degrees are more likely to produce accurate
classification.
To explore whether the combinations between the genes
with 100% depended degrees and other genes with lowerBMC Medical Genomics 2009, 2:64 http://www.biomedcentral.com/1755-8794/2/64
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depended degrees would yield more gene pairs having no
less than 148 samples classified correctly, we added the 16
genes with a 100% depended degree to the 1428 genes
and repeated the above experiment. Surprisingly, the
results were exactly the same as those of the first experi-
ment; i.e., no new gene pair was found. This finding indi-
cates that to obtain perfect classification performance by
combined genes, although the class-discrimination ability
of individual genes is important, the mutual information
complement between individual genes might also be cru-
cial. Additional details regarding this experiment are pro-
vided in Table S1 of the Additional file 4.
Table S2 of the Additional file 4 shows the most seven pair
combinations found in the experiment. Each of the seven
gene pairs generates four rules, which can be simplified
into three equivalent rules. The rules can be used to cor-
rectly classify 148 of 149 samples in the test set, with only
one error (one mesothelioma was misclassified as ADCA).
The detailed rules formed by the seven pairs of genes are
presented in the Additional file 3.
Prostate Cancer dataset
Because of differences in microarray intensity between the
training set and the test set, we first normalized the
attribute values for both sets. Every attribute value was
normalized to a number between -1 and 1. In this dataset,
if the depended degree standard is employed for gene
selection, it is somewhat difficult to find authentically dis-
criminative genes, as no gene has a 100% depended
degree, and the highest depended degree in the training
set is 36%. Therefore, we utilized the α depended degree
as the criterion for gene selection. For α ≥ 0.9, no common
gene was detected among all of the 102 leave-one-out
training sets; when α = 0.85, gene #10493 was found;
when α = 0.80, nine genes were found. Of these nine
genes, we excluded gene #5261 with three distinct values,
and calculated the LOOCV accuracy of the other eight
Table 4: Sixteen genes with high classification accuracy in the Lung Cancer dataset
Probe ID Classification results in LOOCV Classification results in the test set
# Correctly classified samples Accuracy(%) # Correctly classified samples Accuracy(%)
2047_s_at 30 (15/15) 93.75 (93.75/93.75) 122 (11/111) 81.88 (73.33/82.84)
266_s_at 32 (16/16) 100 (100/100) 129 (13/116) 86.58 (86.67/86.57)
32046_at 30 (15/15) 93.75 (93.75/93.75) 133 (12/121) 89.26 (80/90.30)
32551_at 31 (15/16) 96.88 (93.75/100) 134 (14/120) 89.93 (93.33/89.55)
33245_at 30 (15/15) 93.75 (93.75/93.75) 137 (14/123) 91.95 (93.33/91.79)
33833_at 32 (16/16) 100 (100/100) 139 (13/126) 93.29 (86.67/94.03)
35330_at 31 (15/16) 96.88 (93.75/100) 118 (14/104) 79.19 (93.33/77.61)
36533_at 30 (15/15) 93.75 (93.75/93.75) 141 (13/128) 94.64 (86.67/95.52)
37205_at 30 (15/15) 93.75 (93.75/93.75) 135 (12/123) 90.60 (80/91.79)
37716_at 30 (15/15) 93.75 (93.75/93.75) 145 (11/134) 97.32 (73.33/100)
39795_at 31 (16/15) 96.88 (100/93.75) 135 (14/121) 90.60 (93.33/90.30)
40936_at 31 (15/16) 96.88 (93.75/100) 140 (12/128) 93.96 (80/95.52)
41286_at 30 (15/15) 93.75 (93.75/93.75) 121 (13/108) 81.21 (86.67/80.60)
41402_at 31 (16/15) 96.88 (100/93.75) 123 (13/110) 82.55 (86.67/82.09)
575_s_at 32 (16/16) 100 (100/100) 141 (14/127) 94.64 (93.33/94.78)
988_at 30 (15/15) 93.75 (93.75/93.75) 132 (13/119) 88.59 (86.67/88.81)BMC Medical Genomics 2009, 2:64 http://www.biomedcentral.com/1755-8794/2/64
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Table 5: Twenty-five gene pairs with 100% LOOCV accuracy in the Lung Cancer dataset
1st - 2nd Probe ID Classification results in the test set
# Correctly classified samples Accuracy (%)
33754_at - 36562_at 144 (13/131) 96.64 (86.67/97.76)
33754_at - 40496_at 143 (11/132) 95.97 (73.33/98.51)
34105_f_at - 40496_at 141(9/132) 94.64 (60/98.51)
34105_f_at - 36562_at 140 (10/130) 93.96 (66.67/97.01)
37004_at - 40496_at 140 (11/129) 93.96 (73.33/96.27)
36562_at - 37004_at 139 (13/126) 93.29 (86.67/94.03)
38827_at - 40445_at 138 (15/123) 92.62 (100/91.79)
1882_g_at - 36562_at 136 (11/125) 91.28 (73.33/93.28)
1882_g_at - 40496_at 136 (10/126) 91.28 (66.67/94.03)
33907_at - 36562_at 134 (10/124) 89.93 (66.67/92.54)
36562_at - 40496_at 134 (9/125) 89.93 (60/93.28)
1882_g_at - 33907_at 133 (11/122) 89.26 (73.33/91.04)
1882_g_at - 37004_at 132 (13/119) 88.59 (86.67/88.81)
35947_at - 36269_at 132 (12/120) 88.59 (80/89.55)
33907_at - 34105_f_at 131(9/122) 87.92 (60/91.04)
36269_at - 40445_at 131(14/117) 87.92 (93.33/87.31)
35947_at - 40445_at 130 (14/116) 87.25 (93.33/86.57)
38074_at - 38827_at 129 (14/115) 86.58 (93.33/85.82)
33907_at - 40496_at 127(8/119) 85.23 (53.33/88.81)
36269_at - 38074_at 125 (13/112) 83.89 (86.67/83.58)
38074_at - 40445_at 122 (13/109) 81.88 (86.67/81.34)
1117_at - 38827_at 116 (15/101) 77.85 (100/75.37)
1117_at - 36269_at 113 (13/100) 75.84 (86.67/74.63)
1117_at - 35947_at 109 (12/97) 73.15 (80/72.39)
1117_at - 38074_at 106 (14/92) 71.14 (93.33/68.66)BMC Medical Genomics 2009, 2:64 http://www.biomedcentral.com/1755-8794/2/64
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genes. Relatively high LOOCV outcomes were obtained.
Applying the decision rules induced by each of the eight
genes in the training set, we classified the test set and
achieved satisfactory classification results (see Table 6).
The classification rules generated by the eight genes are
presented in the Additional file 5.
As for gene pairs, when α = 0.75 and the threshold of the
positive region sizes caused by single genes was 13, 16
gene pairs were shared by all 102 of the leave-one-out
training sets. The LOOCV accuracy of the 16 gene pairs
was between 81% and 86%, yet there were three pairs of
genes with relatively good classification performance in
the test set (Table 7). The classification rules generated by
the three pairs are presented in the Additional file 5.
We also analyzed the training set based on the depended
degree. We ranked all of the genes in the discretized train-
ing set by their depended degrees. The top two genes,
37639_at and 41755_at, had the highest depended degree
of 36%. When we examined the rules formed by gene
37639_at, we found the following: if g(37639_at) > -
0.491443, then Tumor (100% confidence); if
g(37639_at)  ≤ -0.694377, then Normal (95% confi-
dence). Both rules were highly reliable. Using the two
rules, we correctly classified 33 of the 34 test samples. This
result indicates that gene 37639_at possessed high class-
discrimination power. The rules arising from this gene
indicate that it is relatively highly expressed in tumor sam-
ples. Gene 41755_at produced the following two rules: if
g(41755_at) > 0.261438, then Tumor (100% confidence);
if g(41755_at) ≤ -0.477124, then Normal (100% confi-
dence). Using these two rules, 14 of the 34 test samples
were classified correctly, whereas all 9 samples labeled
"Normal" were classified correctly. The rules implied that
gene 41755_at is expressed at a low level in normal sam-
ples. Apart from 37639_at and 41755_at, gene
38087_s_at produced the following rule: if g(38087_s_at)
> -0.281725, then Normal (100% confidence). We cor-
rectly classified six of nine normal samples using the rule,
indicating that this gene is comparatively highly expressed
in normal samples. Information on the top 20 genes
ranked based on depended degree is provided in the Addi-
tional file 6.
Breast Cancer dataset
In the dataset, when α ≥ 0.8, no shared gene was detected
in all of the 78 leave-one-out training sets; when α = 0.75,
four genes were found; when α = 0.70, 46 genes were
found. Most of these 46 genes had LOOCV accuracy rang-
ing from 70% to 80%, while a few had LOOCV accuracy
slightly less than 70%. Using each of the 46 genes to clas-
sify the test set, we found eight genes by which no less
than 13 of the 19 test samples were classified correctly.
Information on the eight genes is listed in Table 8. The
classification rules generated by each of the eight genes are
available in the Additional file 7. In the dataset, we did
not find any gene pairs with satisfactory classification per-
formance. The best classification accuracy obtained by
gene pairs was 12 test samples classified correctly; accu-
racy was 63.16%.
Leukemia dataset 2
This dataset contains three classes, being a multi-class
classification problem. When α ≥ 0.95, no shared gene
was detected in the 57 leave-one-out training sets; when α
= 0.9 and 0.85, a single gene was found; when α = 0.80,
five genes were found; when α = 0.75, eight genes were
Table 6: Eight genes with high classification accuracy in the Prostate Cancer dataset
Probe ID Classification results in LOOCV Classification results in the test set α
# Correctly classified samples Accuracy (%) # Correctly classified samples Accuracy (%)
32598_at 92 (50/42) 90.20 (96.15/84.00) 23 (17/6) 67.65 (68.00/66.67) 0.85
36491_at 84 (41/43) 82.35 (78.85/86.00) 30 (23/7) 88.24 (92.00/77.78) 0.80
40856_at 85 (46/39) 83.33 (88.46/78.00) 23 (15/8) 67.65 (60.00/88.89) 0.80
32243_g_at 84 (41/43) 82.35 (78.85/86.00) 31 (22/9) 91.18 (88.00/100) 0.80
36601_at 85 (46/39) 83.33 (88.46/78.00) 17 (8/9) 50.00 (32.00/100) 0.80
38044_at 81 (41/40) 79.41 (78.85/80.00) 29 (21/8) 85.29 (84.00/88.89) 0.80
41288_at 88 (41/47) 86.27 (78.85/94.00) 31 (22/9) 91.18 (88.00/100) 0.80
1767_s_at 83 (40/43) 81.37 (76.92/86.00) 24 (22/2) 70.59 (88.00/22.22) 0.80BMC Medical Genomics 2009, 2:64 http://www.biomedcentral.com/1755-8794/2/64
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found; when α = 0.70, 21 genes were identified. Almost
every one of these 21 genes had a high LOOCV accuracy
and good classification performance in the test set. Their
classification information is listed in Table 9. Gene
36239_at had the best LOOCV accuracy and classification
accuracy in the test set. The classification rules induced by
this gene were as follows: if g(36239_at) > 1796.5, then
ALL; if g(36239_at) > 214 and g(36239_at) ≤ 1796.5, then
MLL; if g(36239_at) ≤ 214, then AML; with 95.24%,
93.33%, and 90.48% confidence, respectively. Using
these three rules, we correctly classified 14 of the 15 test
samples; accuracy reached 93.33%. The other genes pro-
duced similar classification rules. The classification rules
generated by every gene can be found in the Additional
file 8. We did not examine gene pairs for the classification,
as the rules induced by gene pairs tended to be complex.
Comparison and analysis of results
Leukemia dataset 1
Other researchers have explored the problem concerned
with the classification of the dataset using rule-based
machine-learning methods. In [7], the authors proposed
Table 7: Three gene pairs with good classification accuracy in the Prostate Cancer dataset
1st - 2nd Probe ID Classification results in LOOCV Classification results in the test set α
# Correctly classified 
samples
Accuracy (%) # Correctly classified 
samples
Accuracy (%)
35178_at - 35277_at 83 (33/50) 81.37 (63.46/100) 26 (20/6) 76.47 (80.00/66.67) 0.7
5
35178_at - 38087_s_at 83 (33/50) 81.37 (63.46/100) 27 (21/6) 79.41 (84.00/66.67) 0.7
5
39331_at - 33121_g_at 86 (38/48) 84.31 (73.08/96.00) 27 (18/9) 79.41 (72.00/100) 0.7
5
Table 8: Eight genes with high classification accuracy in the Breast Cancer dataset
GenBank accession 
number
Classification results in LOOCV Classification results in the test set α
# Correctly classified 
samples
Accuracy (%) # Correctly classified 
samples
Accuracy (%)
NM_012261 57 (21/36) 73.08 (61.76/81.82) 16 (10/6) 84.21 (83.33/85.71) 0.7
0
AW237580 58 (18/40) 74.36 (52.94/90.91) 13 (8/5) 68.42 (66.67/71.43) 0.7
0
U45975 58 (22/36) 74.36 (64.71/81.82) 13 (9/4) 68.42 (75.00/57.14) 0.7
0
AI742029 55 (17/38) 70.51 (50.00/86.36) 13 (11/2) 68.42 (91.67/28.57) 0.7
0
NM_001689 57 (22/35) 73.08 (64.71/79.55) 15 (9/6) 78.95 (75.00/85.71) 0.7
0
TSPYL5 58 (24/34) 74.36 (70.59/77.27) 16 (10/6) 84.21 (83.33/85.71) 0.7
0
NM_000271 57 (20/37) 73.08 (58.82/84.09) 13 (9/4) 68.42 (75.00/57.14) 0.7
0
AL049689 55 (22/33) 70.51 (64.71/75.00) 13 (10/3) 68.42 (83.33/42.86) 0.7
0BMC Medical Genomics 2009, 2:64 http://www.biomedcentral.com/1755-8794/2/64
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first using feature ranking (t-test) and then rough sets
attribute reduction for gene selection. They ultimately
identified one gene, which classified 31 samples correctly
in the test set. This gene was the gene identified in the
present study: gene #4847. However, our method identi-
fied not only this gene, but also other informative genes,
including one gene pair with 100% classification accu-
racy. In [8], the authors also used rough sets for gene selec-
tion. They chose genes with maximum relevance with
respect to the class variable and the maximum positive
interaction between different genes. We also selected
genes with maximum relevance with respect to the class
variable (i.e., the depended degree of a single gene), while
we chose gene pairs with maximum relevance with respect
to the class variable rather than maximum positive inter-
action between the genes, since the maximum positive
interaction between two genes may counteract the
depended degree of a single gene. Because this previous
Table 9: Twenty-one genes with high classification accuracy in the Leukemia dataset 2
Probe ID Classification results in LOOCV Classification results in the test set α
# Correctly classified samples Accuracy (%) # Correctly classified samples Accuracy (%)
36239_at 51 (20/12/19) 89.47 (100/70.59/95) 14 (4/2/8) 93.33 (100/66.67/100) 0.90
39318_at 47 (17/11/19) 82.46 (85/64.71/95) 13 (2/3/8) 86.67 (50/100/100) 0.80
40191_s_at 48 (17/13/18) 84.21 (85/76.47/90) 12 (2/2/8) 80 (50/66.67/100) 0.80
840_at 47 (19/10/18) 82.46 (95/58.82/90) 11 (3/1/7) 73.33 (75/33.33/87.50) 0.80
266_s_at 46 (19/11/16) 80.70 (95/64.71/80) 13 (4/1/8) 86.67 (100/33.33/100) 0.80
37933_at 45 (20/7/18) 78.95 (100/41.18/90) 8 (2/0/6) 53.33 (50/0/75) 0.75
38989_at 43 (19/6/18) 75.44 (95/35.29/90) 12 (3/1/8) 80 (75/33.33/100) 0.75
33833_at 44 (16/10/18) 77.19 (80/58.82/90) 10 (2/0/8) 66.67 (50/0/100) 0.75
32874_at 43 (14/11/18) 75.44 (70/64.71/90) 10 (2/1/7) 66.67 (50/33.33/87.5) 0.7
37487_at 41 (14/7/20) 71.93 (70/41.18/100) 11 (3/0/8) 73.33 (75/0/100) 0.7
31886_at 42 (16/8/18) 73.68 (80/47.06/90) 13 (3/2/8) 86.67 (75/66.67/100) 0.7
35164_at 48 (19/15/14) 84.21 (95/88.24/70) 13 (4/2/7) 86.67 (100/66.67/87.5) 0.7
36905_at 46 (14/12/20) 80.70 (70/70.59/100) 9 (0/1/8) 60 (0/33.33/100) 0.7
37539_at 50 (16/16/18) 87.72 (80/94.12/90) 10 (3/3/4) 66.67 (75/100/50) 0.7
37910_at 45 (18/9/18) 78.95 (90/52.94/90) 9 (1/1/7) 60 (25/33.33/87.5) 0.7
32847_at 44 (18/12/14) 77.19 (90/70.59/70) 11 (4/2/5) 73.33 (100/66.67/62.5) 0.7
35260_at 42 (20/8/14) 73.68 (100/47.06/70) 9 (2/1/6) 60 (50/33.33/75) 0.7
41790_at 47 (19/11/17) 82.46 (95/64.71/85) 13 (3/2/8) 86.67 (75/66.67/100) 0.7
32579_at 48 (15/13/20) 84.21 (75/76.47/100) 11 (2/1/8) 73.33 (50/33.33/100) 0.7
1373_at 47 (16/12/19) 82.46 (80/70.59/95) 10 (1/1/8) 66.67 (25/33.33/100) 0.7
1325_at 47 (19/14/14) 82.46 (95/82.35/70) 10 (3/3/4) 66.67 (75/100/50) 0.7BMC Medical Genomics 2009, 2:64 http://www.biomedcentral.com/1755-8794/2/64
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study assessed classification performance using LOOCV
on a total of 72 samples instead of separating them into
training and test sets, it is impractical to compare their
results with those of the present study. Likewise, in [9] the
authors took into account all attributes depending upon
the degree of dependency. They selected the top λ
attributes (λ = 2, 4, 6, 8, 10, 12, 14, 15) by the degree of
dependency, and found all possible combinations of
these λ attributes as a subset. The authors calculated the
depended degrees of every subset and chose those with
100% depended degrees. Finally, they evaluated the clas-
sification performance of the selected subsets using k-
NNs. In essence, their method was to find the reducts with
limited sizes and to use them for classification. As we
mentioned above, finding all of the reducts is computa-
tionally intensive, even for a small attribute number.
Moreover, one reduct does not indicate high classification
performance. Another difference between our method
and that of [9] is that our classifier is based on rules,
whereas theirs is not. Although they gain a classification
score of 97% with gene subsets of size two, they did not
find any gene pair with a classification score of 100%, and
they did not identify any important genes. In [10], a
method of combining rough sets with GAs was proposed
to classify microarray gene expression patterns. A correct
classification of 90.3% was obtained with a nine-gene
classifier in the dataset.
In [6], the authors used the EPs approach to mark one
important gene, Zyxin, which is our gene #4847. Using
the two rules induced by the gene, the authors accurately
classified 31 samples, the same result as ours. However,
they did not identify any gene pair with higher classifica-
tion performance, as we did. In [11], the authors used
decision trees (Single C4.5, Bagging C4.5, AdaBoost C4.5)
to perform classification tasks on seven publicly available
cancerous microarray datasets, including the ALL-AML
leukemia data. They first employed Fayyad and Irani's
[21] discretization method to filter out noise. The remain-
ing 1038 genes were used in the actual learning process.
Their highest accuracy was 91.2% (31 samples classified
correctly). Since the authors did not report the size of the
pruned decision trees, we have no knowledge of how
many genes they used to reach the highest accuracy. In
[13], 91.2% classification accuracy was achieved by using
the rule classifiers containing gene subsets with sizes rang-
ing from 10 to 40. In [14], the authors utilized a single
pair of genes to correctly classify 31 test set samples.
Besides, a number of different non-rule-based methods
have been proposed for gene selection and cancer classifi-
cation in the dataset. Golub et al. [2] were the first to clas-
sify ALL-AML by gene expression data. The authors
constructed the predictor using 50 informative genes,
trained by weighted voting on the training set. The predic-
tion rates included 36 samples classified correctly, with
two samples labeled "uncertain" in LOOCV, as well as 29
of the 34 samples in the test set classified correctly, with
no predictions made for the remaining five samples. In
[23], the authors applied probabilistic neural networks
(PNNs) to the class prediction of ALL-AML, and achieved
100% prediction accuracy in the test set using the 50-gene
predictors derived from cross-validation tests of the train-
ing set by means of the signal-to-noise statistic feature
selection method. In [24], the authors used a correlation-
based feature (CBF) selector in conjunction with
machine-learning algorithms such as decision trees
(JP48), NB, and SVMs to analyze cancer microarray data.
They reported one noteworthy gene, Zyxin, which classi-
fied 31 samples correctly. In [25], the authors proposed a
maximal margin linear programming (MAMA) method
for the classification of tumor samples based on microar-
ray data. This procedure detected groups of genes and con-
structed models that strongly correlated with particular
tumor types. They achieved 100% prediction accuracy on
the test set using gene subsets ranging in size from 132 to
549. In [26], the authors proposed dimension reduction
using partial least squares (PLS) and classification using
logistic discrimination (LD) and quadratic discriminant
analysis (QDA). By using gene subsets with sizes between
50 and 1500, the authors obtained correct classification of
the test samples ranging from 28 to 33. In [27], the
authors used SVMs trained and gene subsets selected in
the training set to classify samples in the test set, resultng
in the correct classification of between 30 and 32 of the 34
samples. Other SVM-based methods report zero test error
with gene subsets ranging in size from 8 to 30 [28-30].
Table 10 compares our methods with those employed in
previous studies. The table reveals that our classification
results are superior to almost all of those obtained in pre-
vious studies.
In this dataset, we identified 11 genes that show good clas-
sification performance alone or in combination with
another gene. These genes are Zyxin, MGST1, TCRA,
APLP2, CCND3, HKR-T1, KIAA0159, TOP2B, MB-1,
ARHG, and IOTA. Among these, Zyxin, CCND3, HKR-T1,
TOP2B, MB-1, and IOTA also belong to the list of the 50
informative genes identified by Golub et al. [2]; Zyxin is
highly expressed in AML, and the rest are highly expressed
in ALL. Our rules relevant to these genes revealed that
Zyxin, MGST1, APLP2, and ARHG are upregulated in
AML, while TCRA, CCND3, HKR-T1, KIAA0159, TOP2B,
MB-1, and IOTA are upregulated in ALL. These results
demonstrate that our rules are reasonable.
Our method identified an outstanding gene, Zyxin, by
which we classified the test set with 91.2% accuracy. The
gene is also referred to by other researchersBMC Medical Genomics 2009, 2:64 http://www.biomedcentral.com/1755-8794/2/64
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[2,6,7,23,24,26,27,31-36]. Our results and those of other
related studies suggest that the expression level of Zyxin
plays an important role in distinguishing ALL from AML.
Zyxin is a focal-adhesion-associated phosphoprotein with
one domain involved in the control of actin assembly and
three protein-protein adapter domains implicated in the
regulation of cell growth and differentiation. Zyxin may
function as a messenger in the signal transduction path-
way that mediates adhesion-stimulated changes in gene
expression. As noted in [36], cell spreading, proliferation,
and survival are modulated by focal adhesions linking
extracellular matrix proteins, integrins, and the cytoskele-
ton. By supporting the involvement of the microfilament
network in tumor cell behavior, several actin-binding pro-
teins, including Zyxin, a potential regulator of actin
polymerization, may play a role in oncogenesis. The gene
encoding Zyxin maps at 7q32, a chromosomal region
affected in a variety of human cancers. 7q monosomy or
partial deletion of this chromosome arm is frequently
found in myelodysplastic syndrome, acute myeloid, juve-
nile myelomonocytic, and acute lymphocytic leukemias,
as well as in breast carcinoma [37,38]. Valdes et al.
revealed that the actin cytoskeleton-associated protein
Zyxin acts as a tumor suppressor in Ewing tumor cells
[32]. Yagi et al. also identified Zyxin as one of 35 genes
associated with pediatric AML prognosis [31]. Taken
together, these lines of evidence suggest that Zyxin plays
an important role in leukemia pathogenesis.
The aforementioned gene pair, MGST1 vs. TCRA, is capa-
ble of classifying the test set with zero error. Their biolog-
ical meanings are noteworthy. MGST1 is also one of the
Table 10: Comparison of best classification accuracy for the Leukemia dataset 1
Methods (feature selection + classification)a #Selected genes #Correctly classified samples (accuracy) Rule-based classifier
depended degree + decision rules [this work] 1 31 (91.18%) yes
2 34 (100%)
t-test, attribute reduction + decision rules [7] 1 31 (91.18%) yes
attribute reduction + k-NNs [9] 2 33 (97.06%) no
rough sets, GAs + k-NNs [10] 9 31 (91.18%) no
EPs [6] 1 31 (91.18%) yes
discretization + decision trees [11]b unknownc 31 (91.18%) yes
CBF + decision trees [24] 1 31 (91.18%) yes
TSP [14] 2 31 (91.18%) yes
RCBT [13] 10-40 31 (91.18%) yes
neighborhood analysis + weighted voting [2] 50 29 (85.29%) no
signal to noise ratios + PNNs [23] 50 34 (100%) no
MAMA [25] 132-549 34 (100%) no
PLS + LD or QDA [26] 50-1500 28-33 (82.4%-97%) no
prediction strength + SVMs [27] 25-1000 30-32 (88.2%-94.1%) no
SVMs [28-30] 8-30 34 (100%) no
aThe text before "+" states the feature selection method, while that after it states the classification method. The absence of "+" means that the same 
method was used for both feature selection and classification.
bThe decision trees are also involved in feature selection.
c"unknown" means that no related data are provided in the article.
These explanations apply to the other tables.BMC Medical Genomics 2009, 2:64 http://www.biomedcentral.com/1755-8794/2/64
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three core genes screened by Banerjee et al. [10]. In [24],
the gene lies in the first 10 genes selected by the methods
of χ2, InfoGain, ReliefF, and symmetrical uncertainty. In
[23], MGST1 belonged to the set of top 50 genes selected
by signal-to-noise metric (10-fold cross-validation tests).
In our 13 gene pairs with the highest classification per-
formance, MGST1 occurred five times. These facts demon-
strate that MGST1 is significant in the classification of
ALL-AML. Although it has not been identified by other
algorithms, the gene TCRA is clearly important in the
pathogenesis of leukemia [39-41].
APLP2 was one of the first 10 genes selected by Wang et al.
[24], and was identified by Huang et al. [23]. It was also
identified by Yagi et al. [31] as one of 35 genes associated
with pediatric AML prognosis. CCND3 is also listed as one
of the 50 genes selected by Huang et al. [23]. KIAA0159 is
an essential component of the human condensin complex
required for mitotic chromosome condensation. In a brief
examination of related literature, we found that the gene
has not been identified by other algorithms. However,
past studies have indicated that nonrandom chromo-
somal translocations are characteristic of most human
hematopoietic malignancies [42]. Because KIAA0159 is
correlated with the structural maintenance of chromo-
somes, it may be associated with the pathogenesis of
leukemia. TOP2B encodes the protein that is the principal
target of the antileukemic drug etoposide [2,43,44]. MB-1
encodes the Ig-alpha protein of the B-cell antigen compo-
nent. Its dysregulation has been reported to be closely
linked to leukemia and lymphoma [45-48]. ARHG is a
member of the RAS superfamily of genes, which encode
GTP-binding proteins that act in the pathway of signal
transduction and play a key role in the regulation of cellu-
lar functions [49].
In general, the genes identified in the present study are all
directly or indirectly relevant to hematopoietic or cancer-
ous pathogenesis. Therefore, they are likely to play key
roles in the pathogenesis of ALL or AML. It is possible that
they have high performance in distinguishing ALL from
AML.
Lung Cancer dataset
In [9], the authors used rough sets to handle the same
dataset as that considered in the present study. Their best
result was 98% classification accuracy with genes of size
two. As they employed a non-rule-based classifier, k-NN,
no rule was given to explain the result. In [50], in terms of
classification performance, the authors compared predic-
tion by collective likelihoods (PCLs), based on the con-
cept of EPs, with other classification algorithms, including
decision trees, SVMs, and k-NNs. Regarding the Lung Can-
cer dataset, they obtained classification results containing
between 1 and 27 errors. The classification accuracy of our
method is higher than that of other rule-based classifica-
tion algorithms, including PCLs and the decision trees
mentioned in [50]. The highest classification accuracies
on the dataset, using the three different decision trees
reported in [11], were about 93%. In [13], the best result
was 98% classification accuracy. In the initial research
article on the dataset [15], the authors reported 99% clas-
sification accuracy using six genes. Table 11 compares our
results with those of other studies, revealing that our out-
comes matched or outperformed those obtained using
other methods.
We now explain in more detail the results presented in
[15]. The article proposed to use the expression levels of a
small number of genes for the diagnosis of MPM and lung
cancer. The authors screened out eight genes with marked
differences in average expression levels between the tumor
types in the training set. They then calculated 15 expres-
sion ratios for each sample by dividing the expression
value of each of the five genes expressed at relatively
higher levels in MPM by the expression value of each of
the three genes expressed at relatively higher levels in
ADCA. Next, they employed these ratios for the test set.
Samples with ratio values > 1 were classified as MPM, and
those with ratio values < 1 were classified as ADCA. They
achieved classification accuracies ranging from 91% to
98%. In essence, they also utilized gene pairs for classifi-
cation. Yet, when following the same protocol for training
and testing, our results are superior to theirs, in that they
used three ratios (i.e., six genes) to reach 148 of 149 cor-
rectly classified samples, while we obtained the same
result using each of the seven gene pairs directly selected
from the training set without the LOOCV procedure. Of
note, six of the eight genes selected in this earlier study
were also identified in the present study. The six genes are
PTGIS, CD200, TACSTD1, TTF1, ANXA8, and CALB2, the
first three of which have a 100% depended degree.
The genes selected by our method are associated primarily
with the pathogenesis of MPM or ADCA or some other
tumor. According to our rules, JUP, CD24, PRKCD,
MAPK13, TACSTD2, DKFZP564O0823 protein,
TACSTD1, CEACAM1, XBP1, TTF1, SFTPB, AGR2, ELF3,
EVI1, and CDA are highly expressed in ADCA, while EGF,
SPTAN1, FLNC, PTGIS, FBXL7, CD200, AP2 M1, ANXA8,
HAS1, CALB2, GFPT2, KIAA0427, C1S, EIF4G3, TGM1,
Adamts3, hypothetical protein dJ465N24.2.1, and AP3S1
are highly expressed in mesothelioma. CALB2 encodes
calretinin, which is a component of several immunohisto-
chemical panels currently used in the diagnosis of MPM
and lung cancer [15]. HAS1 is a member of gene family
HA, which has been correlated with tumor metastasis. In
[51], HAS1 was identified as a prognostic gene for mes-
othelioma. In [52], HAS1 belongs to the list of the genes
with elevated expression levels in C1 MPM tumors. WeBMC Medical Genomics 2009, 2:64 http://www.biomedcentral.com/1755-8794/2/64
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have one rule arising from HAS1: if g(HAS1) > 7.3, then
MPM. This rule is consistent with the results of [51,52].
ANXA8, PTGIS, and CLAB2 are also marked as more
highly expressed genes in C1 MPM tumors [52]. These
observations are supported by the following rules of the
present study: if g(ANXA8) > 130.8, then MPM; if
g(CALB2) > 490.5, then MPM; if g(PTGIS) > 193.25, then
MPM. Other genes that we chose (e.g., CD24, TACSTD1,
TACSTD2, CEACAM1, and PRKCD) are correlated with
lung carcinoma or other tumors. TTF1 is a transcription
factor that regulates the expression of multiple genes
involved in lung development. It is preferentially
expressed in ADCAs of the lung and has been investigated
as a potential prognostic parameter in patients with lung
cancer [53-56].
Prostate Cancer dataset
Regarding the Prostate Cancer dataset, a previous study
reported a 95% prediction rate using a gene pair [14]. The
best classification results on the dataset, based on three
different decision tree approaches (Single C4.5, Bagging
C4.5, and AdaBoost C4.5), are 67.65%, 73.53%, and
67.65%, respectively [11]. In [13], a 97% classification
result was reported, but the employed gene numbers were
not provided. In [18], the authors built predictors using a
k-NN algorithm, and achieved 77% and 86% prediction
accuracy on the test set with 4 and 16 genes, respectively.
Table 12 summarizes the best results of classification on
the dataset.
In the Prostate Cancer dataset, we identified 13 genes
using the LOOCV approach. Seven of the eight single
genes had relatively good classification performance, of
which five genes had established names: NRP2,
TMSB15A, PEDF, FAM107A and TGFB3. Our rules imply
that TMSB15A, also named thymosin beta15, is highly
expressed, while NRP2, PEDF, FAM107A and TGFB3 are
expressed at low levels in tumor tissue. As revealed in [57],
thymosin beta15 levels are elevated in human prostate
cancer and correlate positively with the Gleason tumor
grade. Thymosin beta 15 may represent a potential new
biochemical marker for the progression of human pros-
tate cancer; our rules strengthen this perspective. Previous
investigations have revealed that PEDF expression is neg-
atively correlated with tumor malignancy [58-62]; our
rules support this viewpoint. FAM107A has been consist-
ently reported to be downregulated in human cancer
[63,64]; that conforms to our rules. In the gene pairs, our
rules indicate that KIAA0762 is downregulated, while
TUBB and RGS10 are upregulated in tumor tissue; how-
ever, there exists insufficient evidence to directly link the
three genes with prostate cancer.
The three genes that we identified directly from the train-
ing set are hepsin (37639_at), KIAA0977 (41755_at), and
Table 11: Comparison of best classification accuracy for the Lung Cancer dataset
Methods (feature selection + classification) #Selected genes #Correctly classified samples (accuracy) Rule-based classifier
depended degree + decision rules [this work] 1 145 (97.34%) yes
2 144 (96.64%)
attribute reduction + k-NNs [9] 2 146 (97.99%) no
PCLs [50] unknown 146 (97.99%) yes
C4.5 [50] 1 122 (81.88%) yes
Bagging [50] unknown 131 (87.92%) yes
Boosting [50] unknown 122 (81.88%) yes
SVMs [50] unknown 148 (99.33%) no
k-NNs [50] unknown 148 (99.33%) no
discretization + decision trees [11] unknown 139 (93.29%) yes
RCBT [13] 10-40 146 (97.99%) yes
gene expression ratios [15] 6 148 (99.33%) noBMC Medical Genomics 2009, 2:64 http://www.biomedcentral.com/1755-8794/2/64
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S100A4 (38087_s_at). Hepsin performs reasonably well
in differentiating two classes of samples, and the latter two
genes are good indicators of normal samples. Hepsin is
the human hepatoma mRNA for serine protease. Numer-
ous studies have revealed that it is closely linked to pros-
tate cancer. Hepsin is widely reported to be highly over-
expressed in more than 90% of human prostate tumors,
making it a significant marker and a target for prostate
cancer [65-72]. In [18], hepsin was identified as the first
over-expressed gene in tumor samples and was selected as
one of 16 genes used for creating a prediction model. All
of these outcomes strongly support our rules involved in
hepsin. Another gene, KIAA0977, has also been listed as a
highly expressed gene in tumor samples [18]. The third
gene, S100A4, was associated with cancer pathogenesis,
chromosomal rearrangements and altered expression of
which have been implicated in tumor metastasis [73-75].
In [18], S100A4 was identified as one of the highly
expressed genes in normal samples and chosen as one
member of a 16-gene model of prediction. In addition,
[76] noted that S100A4 protein was not expressed in
benign or malignant prostatic epithelium or in LNCaP
and Du145 cells. Our rules related to this gene support
these previous findings. A surprising result is that many
observations have revealed that S100A4 is over-expressed
in most other tumors [77-82], yet in [76] the authors sug-
gested that the mechanism of changes in the expression
level of S100A4 may involve methylation of the S100A4
gene.
Breast Cancer dataset
In the Breast Cancer dataset, our best LOOCV accuracy
was 74.34%, and the highest classification accuracy in the
test set was 84.21% with one gene. In [19], the authors
reported 83.33% LOOCV accuracy and 89.47% accuracy
in the test set using the 70-gene predictor. These predic-
tion results are moderately superior to those attained in
the present study, although using a much larger number
of genes. Likewise, Tan et al. [11] obtained a slightly better
classification outcome than that of the present study,
although they used far more genes. Table 13 lists some of
the best classification results for this dataset, as obtained
using a variety of methods.
In this dataset, we identified eight genes with relatively
high individual classification performance. Our rules
indicated that the overexpression of ATP5G3, TSPYL5, or
NPC1 means an unfavorable prognosis, while the overex-
pression of HS1119D91, Contig38726_RC, PIB5PA,
Contig51517_RC, or LOC63923 implies a favorable prog-
nosis. TSPYL5 had the best classification accuracy in our
model; it was also chosen as one of 70 prognostic marker
genes and ranked first according to the correlation coeffi-
cient with the two prognostic groups [19]. It follows that
Table 12: Comparison of best classification accuracy for the Prostate Cancer dataset
Methods (feature selection + classification) #Selected genes #Correctly classified samples (accuracy) Rule-based classifier
depended degree + decision rules [this work] 1 31 (91.18%) yes
2 27 (79.41%)
TSP [14] 2 32 (94.12%) yes
PCLs [50] unknown 33 (97.06%) yes
discretization + Single C4.5 [11] unknown 23 (67.65%) yes
discretization + Bagging C4.5 [11] unknown 25 (73.53%) yes
discretization + AdaBoost C4.5 [11] unknown 23 (67.65%) yes
RCBT [13] unknown 33 (97.06%) yes
SVMs [13] unknown 27 (79.41%) no
signal to noise ratios + k-NNs [18]d 42 6  ( 7 7 . 2 % ) n o
16 29 (85.7%) no
dIn [18], as both raw and normalized datasets were used, two groups of prediction results were obtained. Here, we chose their results from the 
normalized dataset. Another small difference is that we obtained the dataset from the Kent Ridge Bio-medical Data Set Repository, where the 
prostate test set includes 25 tumor and 9 normal samples instead of the 27 tumor and 8 normal samples studied in [69]. To facilitate comparison, 
the correctly classified sample numbers were calculated according to the total of 34 samples.BMC Medical Genomics 2009, 2:64 http://www.biomedcentral.com/1755-8794/2/64
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our gene selection approach is reasonable. In [83], the
authors proposed a prognostic predictor of breast cancer
with multiple fuzzy neural models using the same dataset.
Surprisingly, although these methods are distinct from
those of the present study, there is an overlap of 3 genes
between the 10 highest-ranked genes they chose for pre-
diction and our 8-gene group.
Leukemia dataset 2
Although this dataset is involved in a multi-class classifi-
cation problem, we still achieved relatively good classifi-
cation outcomes. Our best prediction rate was 93.33% in
the test set and 89.47% LOOCV accuracy in the training
set, each by one gene, compared with a 90% prediction
rate in the test set by 100 genes and 95% LOOCV accuracy
in the training set by 40 genes, as reported by Armstrong
et al. [84]. In addition, Wang et al. reported 100% LOOCV
accuracy in all 72 samples using 26 genes; however, their
methods were not verified by an independent test set.
These outcomes are presented in Table 14.
Regarding the Leukemia dataset 2, each chosen gene
induced 3 rules with the following form: if g(x) > a, then
class 1; if b < g(x) ≤ a, then class 2; if g(x) ≤ b, then class 3.
That is, if the expression level of gene x in a sample is rel-
atively high, then the sample is assigned to class 1; if the
expression level is moderate, then the sample is assigned
to class 2; if the expression level is relatively low, then the
sample is assigned to class 3. According to the standard,
we predicted the class of every sample based on its expres-
sion value on the chosen genes. In total, we identified 21
genes with comparatively strong prediction power. Of
these genes, 36239_at (OBF-1) and 31886_at (human
placental cDNA coding for 5' nucleotidase) are also con-
tained in the best 26-gene prediction model proposed in
[85]. It is noteworthy that OBF-1 was ranked as the top of
these 26 genes, and it yields the best prediction outcome
in our methods. This finding demonstrates that our deci-
sion-rule-based classification approach is superior to the
clustering analysis-based classification approach of [83],
as we achieved a similar level of classification perform-
ance using just a single gene instead of 26. In addition, six
of the genes identified using the present methods are
mentioned as high-class discrimination genes in [20].
These six genes are OBF-1, CD24, MLCK, KIAA0867,
SMARCA4, and cDNA wg66 h09. Indeed, our rules
induced by each of the six genes are well in accordance
with the outcomes presented in [20], demonstrating that
these genes are highly expressed in ALL, moderately
expressed in MLL, and expressed at a low level in AML.
Table 13: Comparison of best classification accuracy for the Breast Cancer dataset
Methods (feature selection + classification) #Selected genes #Correctly classified samples (accuracy) Rule-based classifier
α depended degree + decision rules [this work] 1 16 (84.21%) yes
TSP [14] 2 79.38%e yes
RBF [50] 67 79.38%e yes
discretization + decision trees [11] unknown 17 (89.47%) yes
correlation coefficient [19] 70 17 (89.47%) no
eLOOCV result in the total of 97 samples.
Table 14: Comparison of best classification accuracy for the Leukemia dataset 2
Methods (feature selection + classification) #Selected genes #Correctly classified samples (accuracy) Rule-based classifier
α depended degree + decision rules [this work] 1 14 (93.33%) yes
HykGene + k-NNs, SVMs, C4.5, NB [85] 26 100%f noi
signal to noise ratios + k-NNs [20] 40 95%g no
100 9 (90%)h
fLOOCV result in a total of 72 samples.
gLOOCV result in a total of 57 training samples.
hIn [20], only 3 of 8 AML testing samples in the dataset were mentioned. Thus, their test set contained 10 rather than 15 samples.
iExcept for C4.5, all the others are not rule-based classifiers.BMC Medical Genomics 2009, 2:64 http://www.biomedcentral.com/1755-8794/2/64
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In summary, we have identified some important genes
that not only possess potent classification ability but also
are closely associated with the pathogenesis of specific or
general cancers in every dataset. In the Leukemia dataset
1, significant genes such as Zyxin and MGST1, frequently
identified by previous researchers, were also identified in
the present study. At the same time, we selected some
genes rarely identified by other methods (e.g., TCRA,
KIAA0159, and MB-1), which have been proven to corre-
late directly or indirectly with AML-ALL class prediction.
Our results demonstrate that the genes with excellent per-
formance in AML-ALL classification are not only the
markers of hematopoietic lineage, but also related to gen-
eral cancer pathogenesis. Therefore, the genes we have
identified, which are useful for AML-ALL classification, are
also indicators of cancer pathogenesis and pharmacology.
This is consistent with the conclusion of Golub et al. [2].
In the Lung Cancer dataset, we succeeded in identifying
highly discriminative genes (e.g., CALB2, HAS1, and
ANXA8) implicated in the pathogenesis of MPM, ADCA,
or other tumors. In the Prostate Cancer dataset, we identi-
fied some important genes with significant biological rel-
evance, such as TMSB15A, PEDF, hepsin, KIAA0977, and
S100A4. In particular, hepsin, which has the highest
depended degree, has been reported to have significant
involvement in the pathogenesis of prostate cancer. In the
Breast Cancer dataset, TSPYL5 was regarded as the most
valuable prognostic marker by our methods and by the
correlation-based approach used in [19]. In the Leukemia
dataset 2, we identified OBF-1 and others, which excel-
lently separate ALL, MLL, and AML. Overall, the majority
of genes relevant to tumors encode proteins functioning
in cell growth, motility and differentiation, apoptosis,
angiogenesis, metabolism, chromosomal rearrangement
and translocation, and immune reactions.
Discussion
Microarray-based cancerous gene classification is a partic-
ular classification problem: the quantity of features
(genes) greatly exceeds the number of instances (sam-
ples). As the majority of features are redundant for the
classification task, feature selection is of vital importance.
At the same time, the discovery of important gene markers
relevant to cancer remains a significant task. To this end,
we proposed a method of feature selection based on the
depended degree of attributes by classes, by which we
screened single or double informative genes for classifica-
tion. We built classifiers on the basis of the decision rules
arising from these genes or gene pairs. Using just a small
number of features, we gained high-quality solutions to
classification problems in the analysis of high-dimen-
sional gene expression data.
In general, our approach has advantages over other meth-
ods. For example, our methods are based on rules. In con-
trast to non-rule-based methods (e.g., SVMs, ANNs, GAs,
k-NNs and NB) rule-based methods are understandable
and logical, so that biologists and clinicians are more
inclined to adopt them. More importantly, as we utilize
very few genes (one or two) to construct classification
rules, the derived classifiers are quite simple and easily
understood. Hence, our rule-based method has an advan-
tage over other rule-based methods that involve more
complicated rules.
Our work is consistent with the opinion expressed in
[86,87]: simple approaches perform well in microarray-
based cancer prediction. This opinion is supportive of the
principle of Occam's razor. It is not strange that single or
double genes can result in accurate classification of can-
cer, as the single genes or gene pairs might be the potential
biomarkers of cancer [17]. In contrast, when complex pre-
diction models achieve highly accurate prediction rates
using a large number of genes, it is difficult to assess which
genes are the significant biomarkers of cancer. In fact,
molecular classification of cancer is a specific classifica-
tion problem, as it incorporates essential double implica-
tions: classification and identifying biomarkers of cancer.
Although accurate classification must be guaranteed, the
detection of biomarkers is also important, sometimes
even more so than accuracy; otherwise, the (accurate) clas-
sification results have only limited significance. Because
simple classification models may be advantageous in
finding important biomarkers with a high classification
accuracy, it is worthwhile applying simple prediction
approaches rather than complex methods for the molecu-
lar classification of cancer. Furthermore, it is better to uti-
lize simple rule-based classification methods because of
their interpretability.
It should be noted that because we only verified the clas-
sification accuracy using one independent test set for
every dataset, the stability of the classifier was not
assessed. That is, if the different training and test sets are
chosen, the classification results maybe vary, although not
necessarily significantly deviate from our estimates. There-
fore, the present classification accuracies only roughly
reflect the quality of our classifiers. One more unbiased
estimate should be based on the average of the results
obtained by repeating the partition of samples between
training and test set many times, which is time consuming
for our methods.
Conclusion
Our microarray-based cancer classification methods are
simple and interpretable relative to most other
approaches, since our classifiers are based on decision
rules, and the decision rules are based on single or double
genes. We demonstrated the efficacy of our methods by
their application to several well-known gene expressionBMC Medical Genomics 2009, 2:64 http://www.biomedcentral.com/1755-8794/2/64
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datasets. In these datasets, our methods identified the sin-
gle genes or gene pairs that perform well in distinguishing
different classes of cancer. Moreover, a large proportion of
the genes screened by our methods may have biological
relevance to malignancy or cell type, meaning that they
can be regarded as candidate biomarkers of cancer.
Generally speaking, simple classification models are capa-
ble of giving good performance in most classification
problems, including the molecular classification of can-
cer, if a small number of features are correctly selected
[6,12,14,88,89]. The present results lend support to this
notion. One recommended follow-up study is to combine
our methods with other established machine-learning
algorithms to address the problem of molecular classifica-
tion of cancer.
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